IP Library Granted Patent US 7,628,977
Granted Patent B2
US 7,628,977 · App. 10/420,071 · Granted Dec 8, 2009

Particles for inhalation having sustained release properties

Assignees: Massachusetts Institute of Technology; The Penn State Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,628,977
App. No.
10/420,071
Granted
Dec 8, 2009
Kind
B2
Abstract

The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.

Claims (10)

1. A method for delivery via the pulmonary system comprising:

administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles in dry powder form comprising a bioactive agent in association with a charged lipid wherein the charged lipid is present in an amount from 10 to about 99% by weight and has an overall negative net charge and wherein release of the agent is sustained, wherein the lipid is a 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)] or a 1,2-diacyl-sn-glycerol-3-phosphate.

2. The method of claim 1 , wherein the 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)] lipid is represented by Formula I:

wherein,

R 1 and R 2 are independently an aliphatic group having from about 3 to about 24 carbons.

3. The method of claim 1 , wherein the 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)] lipid is 1,2-distearoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DSPG), 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG), 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol)] (DPPG), 1,2-dilauroyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DLPG), 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DOPG) or any combination thereof.

4. The method of claim 1 , wherein the 1,2-diacyl-sn-glycerol-3-phosphate is represented by the Formula II:

wherein,

R 1 and R 2 are independently an aliphatic group having from about 3 to about 24 carbons.

5. The method of claim 1 , wherein the 1,2-diacyl-sn-glycerol-3-phosphate lipid is 1,2-dimyristoyl-sn-glycero-3-phosphate (DMPA), 1,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA), 1,2-dilauroyl-sn-glycero-3-phosphate (DLPA), 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA) or any combination thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Apr 12, 2011
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026108/0632 →
Continuity (9)
Continuation In Part 0975210600 · Dec 29, 2000
Continuation In Part 0939423300 · Sep 13, 1999
Continuation In Part 0897179100 · Nov 17, 1997
Continuation In Part 0878442100 · Jan 16, 1997
Continuation In Part 0873930800 · Oct 29, 1996
Continuation In Part 0865557000 · May 24, 1996
Provisional Application 6005900400 · Sep 15, 1997
Related Publication 20040062718A1 · Apr 1, 2004
Related Publication 20080253971A9 · Oct 16, 2008